Monsanto Company

Oxford University Innovation Ltd

United Therapeutics Corporation

Other

Thomas Jefferson University

Emergent Virology LLC

G.d. Searle & Company

The Chancellor, Masters and Scholars of the University of Oxford

The University of Oxford

Terry D Butters

Raymond A Dwek

Frances M Platt

Gabrielle R Neises

Nicole Zitzmann

Urban Ramstedt

Brennan Klose

Timothy Michael Block

Gary S Jacob

Anand Mehta

George W J Fleet

Donald H Picker

Sandra Carrouee

David Durantel

Baruch S Blumberg

George WJ Fleet

Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars.

Iminosugars and methods of treating viral diseases

Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C-Calkyl group. The long chain N-alkyl compounds and oxa-substituted derivatives thereof can be used in the treatment of viral infections, in particular hepatitis B virus or hepatitis C virus, in a cell or an individual. For example, the long chain N-alkyl compounds or oxa-substituted derivatives thereof can be derived from piperidines, pyrrolidines, phenylamines, pyridines, pyrroles, or amino acids.

Long chain N-alkyl compounds and oxa-derivatives thereof

A compound of Formula I are provided: wherein R is: Ris a substituted or unsubstituted alkyl group; Ware independently selected from hydrogen, substituted or unsubstituted alkyl groups, substituted or unsubstituted haloalkyl groups, substituted or unsubstituted alkanoyl groups, substituted or unsubstituted aroyl groups, or substituted or unsubstituted haloalkanoyl groups; Xare independently selected from H, NO, N, and NH; Y is absent or is a substituted or unsubstituted C-alkyl group, other than carbonyl; Z is selected from a bond or NH, provided that when Z is a bond, Y is absent, and provided that when Z is NH, Y is a substituted or unsubstituted C-alkyl group, other than carbonyl. Also provided are D-arabinitol compounds, methods for preparing such compounds and compositions of such compounds, and methods of using such compounds.

Deoxynojirimycin and D-arabinitol analogs and methods of using

Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Togaviridae family using iminosugars, such as DNJ derivatives.

Iminosugars and methods of treating togaviral diseases

Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Bunyaviridae or Togaviridae family using iminosugars, such as DNJ derivatives.

Iminosugars and methods of treating bunyaviral and togaviral diseases

Long chain n-alkyl compounds and oxa-derivatives thereof

Methods for treating lipid storage diseases using compounds that inhibit glucosyltransferase enzymes are disclosed herein. The invention relates to the treatment of lipid storage disease with compounds that inhibit glucosyltransferase activity in the affected cells. It relates particularly to the use of 1,5-dideoxy-1,5-imino-D-glucitol and derivatives thereof.

Inhibition of glycolipid biosynthesis

A novel method is disclosed for the treatment of a patient affected with Gaucher's disease or other such glycolipid storage diseases. The method comprises administering to said patient a therapeutically effective amount of a long-chain N-alkyl derivative of deoxynojirimycin to alleviate or inhibit the glycolipid storage disease. The long-chain alkyl group has from nine to about 20 carbon atoms and preferably is nonyl or decyl.

Method for treatment of glycolipid storage diseases

Methods for inhibiting morphogenesis of host cell membrane-budding viruses and infections caused thereby using compounds that inhibit host cell glucosidase or glucosyltransferase enzymes. Methods for treating lipid storage diseases using compounds that inhibit glucosyl transferance enzymes.

Inhibition of membrane-associated viral replication

Novel N-alkyl derivatives of deoxygalactonojirimycin are provided in which said alkyl contains from 3-6 carbon atoms. These novel compounds are useful for selectively inhibiting glycolipid synthesis.

Deoxygalactonojirimycin derivatives

A method is disclosed for the treatment of Tay-Sachs disease comprising subjecting said cells to a glycolipid inhibitory effective amount of an N-alkyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol in which said alkyl contains from 2-8 carbon atoms.

Growing community of inventors

Oxford, United Kingdom

Terry D Butters